Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on October 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 28, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of the company's common stock.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised options to acquire a total of 8,334 shares at prices of $120.26 and $117.76.
• Simultaneously, he sold a total of 4,800 shares at a price of $350 per share.
• Some of the option exercises were 'sell-to-cover' transactions, where a portion of the acquired shares were immediately sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 7,512 shares of common stock and holds options for 240,484 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing plan. There's no indication of positive or negative implications for the company's performance.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Industry Context

Stock transactions by company executives are common and closely monitored by investors. The use of a 10b5-1 plan is a standard practice to allow insiders to sell shares while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
• The exercise and sale of shares by executives are typical occurrences, especially when part of a pre-planned trading strategy.
• Comparable companies in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Biogen, also see regular stock transactions by their executives.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential dilution from the option exercises and the effect of the sales on the stock price, although the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates